Navigation Links
Another Use For Epilepsy Drugs

Based on finding of a recent study researchers say the drug gabapentin (Neurontin) taken at 2,400 milligrams a day is an effective preventive // measure for people with chronic daily headaches.

Gabapentin is an approved anti-epileptic drug. Studies have also shown its success in treating other pain-related health issues like diabetic neuropathy, postherpetic neuralgia, and migraine headache. Since gabapentin often reduces migraines by more than 50 percent and chronic daily headaches often have migraine-like features, researchers in Australia conducted a double-blind, placebo-controlled study to determine the drug's specific effect on chronic daily headaches. This type of study is the gold standard of clinical research studies where neither the researchers nor the participants know who received the drug or an identical dummy substance, called a placebo.

For the study researchers recruited 133 patients who had headaches at least 15 days every month that lasted more than four hours at a time. The patients were randomly selected to receive gabapentin or a placebo for six weeks. After that period, none of the patients received either treatment for a week, and then each group switched to the opposite treatment for a second six weeks.

Results showed 36 percent of the patients taking 2,400 milligrams of gabapentin a day stopped having chronic daily headaches. Negative effects of the drug included vomiting, dizziness, dysarthria (problems speaking), sleepiness, and constipation.
'"/>




Page: 1

Related medicine news :

1. Another ray of hope for Arthritis Sufferers
2. Another injectable contraceptive Pill approved by FDA
3. The Possibility Of Fighting HIV with Another Virus Questioned
4. New Research Has Found Another Use For Botox
5. Yet Another Harmful Consequence Of Smoking
6. Another Treatment Option for Benign Tumors
7. Yet Another Treatment Option For Cancer
8. Another Alternative For Diabetics On Insulin
9. Another Cause of Thyroid Cancer Discovered
10. Yet Another Use For Cell Phone Cameras
11. Yet Another Use For Cocoa Flavonols
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/23/2017)... ... June 23, 2017 , ... Radabaugh & Associates, a ... and business owners in North Central West Virginia, is embarking on a cooperative ... abled residents in the region. , The Stepping Stones organization offers a series ...
(Date:6/22/2017)... California (PRWEB) , ... June 22, 2017 , ... Groove ... spread the word about their high performance silicon wedding bands and all-purpose rings. Whether ... are the active, silicone rings designed just for you. , From the rock face ...
(Date:6/22/2017)... ... June 22, 2017 , ... A June 12 article in ... about an apparent lack of oral hygiene by an aged parent who had recently ... matters, suggests a number of steps, including scheduling a dentist visit. Northridge Dental Works, ...
(Date:6/20/2017)... York City (PRWEB) , ... June 20, 2017 , ... After months of negotiations, FaceCradle ... QVC Network on Wednesday, June 21. , “Introducing our product on QVC is ... for us to promote our travel pillow to more than 90 million homes in the ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... the introduction of school choice can promote economic development in economically distressed urban ... has, according to the report, contributed to the economic development of the city ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... , May 22, 2017  As the ... a whole continue to make the revolutionary shift ... increasingly important for ensuring positive patient outcomes and ... stakeholders are shifting focus away from clinical trials ... effects of long-term specialty drug therapy utilization in ...
(Date:5/18/2017)... WHIPPANY, N.J. , May 17, 2017  Bayer ... growing oncology portfolio will be presented at the 53 ... Clinical Oncology (ASCO), taking place June 2-6 in ... being presented at ASCO span prostate, colorectal, liver and ... subgroup analysis from the Phase II CHRONOS-1 trial of ...
(Date:5/15/2017)... , May 15, 2017 Enterin Inc., a ... and developing novel compounds to treat Parkinson,s disease (PD), ... study is a Phase 1/2a randomized, controlled, multicenter study involving ... It will enroll 50 patients over a 9-to-12-month period. The ... in 10 patients with PD. Participating sites include ...
Breaking Medicine Technology: